Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma

Acceleron Pharma logoAcceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XLRN
  • CUSIP:
Key Metrics:
  • Previous Close: $30.19
  • 50 Day Moving Average: $34.09
  • 200 Day Moving Average: $32.82
  • 52-Week Range: $37,596,000.00 - $22.67
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.27
  • P/E Growth: 0.00
  • Market Cap: $1.10B
  • Outstanding Shares: 37,596,000
  • Beta: 1.58
  • Net Margins: -190.41%
  • Return on Equity: -30.00%
  • Return on Assets: -25.74%
  • Current Ratio: 9.28%
  • Quick Ratio: 9.28%
Additional Links:
Companies Related to Acceleron Pharma:

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 1 Hold Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.90)
Consensus Price Target: $48.50 (66.10% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
DateFirmActionRatingPrice TargetDetails
10/7/2016Leerink SwannReiterated RatingOutperformView Rating Details
9/29/2016Citigroup Inc.Initiated CoverageNeutral$40.00View Rating Details
9/28/2016FBR & CoReiterated RatingBuyView Rating Details
9/28/2016Credit Suisse Group AGReiterated RatingBuy$42.00View Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00View Rating Details
8/5/2016Morgan StanleyReiterated RatingBuy$58.00View Rating Details
6/13/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $42.00View Rating Details
6/10/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details
4/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
3/3/2015JMP SecuritiesBoost Price TargetMarket Outperform$52.00 -> $58.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Acceleron Pharma (NASDAQ:XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)ViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$3.80 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)ViewN/AView Earnings Details
8/12/2014($0.55)($0.54)ViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
Current Year EPS Consensus Estimate: $-1.62 EPS
Next Year EPS Consensus Estimate: $-2.2 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.10)($0.27)
Q2 20163($0.59)($0.45)($0.52)
Q3 20162($0.63)($0.54)($0.59)
Q4 20162($0.69)($0.59)($0.64)
(Data provided by Zacks Investment Research)


Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 75.51%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
News IconShare Value Diminishing Over Past Month: Acceleron Pharma, Inc. (NASDAQ:XLRN) - CSZ News (NASDAQ:XLRN) - October 15 at 7:53 PM
News IconZMapp, the experimental Ebola drug, falls short in clinical trial that couldn't find enough new patients (NASDAQ:XLRN) - October 13 at 8:25 PM
News IconAcceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with ... (NASDAQ:XLRN) - October 13 at 12:16 PM logoAcceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial (NASDAQ:XLRN) - October 13 at 12:16 PM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : October 13, 2016 (NASDAQ:XLRN) - October 13 at 12:16 PM
News IconInsiders are Curtailing Holdings in Acceleron Pharma, Inc. (NASDAQ:XLRN) - CSZ News (NASDAQ:XLRN) - October 10 at 7:37 PM
News IconStock Target Update on Acceleron Pharma Inc. (NASDAQ:XLRN) - Recall News (NASDAQ:XLRN) - October 4 at 7:40 PM logoAcceleron Pharma (XLRN) CEO John Knopf to Retire; Habib Dable to Replace (NASDAQ:XLRN) - September 29 at 8:02 PM logoCoverage initiated on Acceleron Pharma by Citigroup (NASDAQ:XLRN) - September 29 at 8:02 PM logo​John Knopf to retire as CEO of Acceleron Pharma (NASDAQ:XLRN) - September 28 at 7:56 PM logoAcceleron Pharma (XLRN) CEO John Knopf to Retire; Habib Dable ... - (NASDAQ:XLRN) - September 28 at 5:55 AM logoAcceleron Pharma tabs Bayer exec as next CEO - MarketWatch - MarketWatch (NASDAQ:XLRN) - September 27 at 8:04 PM logo4:02 pm Acceleron Pharma announces Habib Dable will succeed John Knopf as CEO upon his retirement effective Dec 1, 2016 (NASDAQ:XLRN) - September 27 at 8:04 PM logoACCELERON PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financi (NASDAQ:XLRN) - September 27 at 8:04 PM logoAcceleron Pharma tabs Bayer exec as next CEO (NASDAQ:XLRN) - September 27 at 8:04 PM logoAcceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor (NASDAQ:XLRN) - September 27 at 8:04 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN)'s Expectation Of $251.47 In Sales - Investor Newswire (NASDAQ:XLRN) - September 25 at 6:59 PM logoCan Acceleron Pharma Inc. (NASDAQ:XLRN) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:XLRN) - September 24 at 7:13 PM
News IconAcceleron Pharma Inc (NASDAQ:XLRN)'s SVP - Bus. Dev. - GC & Secretary John Quisel Unloaded 45952 Shares of ... - Post News (NASDAQ:XLRN) - September 23 at 7:31 PM logoEPS Estimate For Acceleron Pharma Inc. (NASDAQ:XLRN) Set At $-0.61 - Investor Newswire (NASDAQ:XLRN) - September 21 at 12:01 PM logoETF’s with exposure to Acceleron Pharma, Inc. : September 20, 2016 (NASDAQ:XLRN) - September 21 at 12:01 PM logoExpected For Acceleron Pharma Inc. (NASDAQ:XLRN) Sales Of $251.47 - Investor Newswire (NASDAQ:XLRN) - September 18 at 7:35 PM
News IconConsensus Take: Acceleron Pharma Inc. (NASDAQ:XLRN) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:XLRN) - September 17 at 7:32 PM
News IconConsensus Take: Acceleron Pharma Inc. (NASDAQ:XLRN) Earnings ... - Frisco Fastball (NASDAQ:XLRN) - September 16 at 7:51 PM
News IconCould Acceleron Pharma Inc Change Direction After Today's Huge Increase? - Chester News (NASDAQ:XLRN) - September 15 at 8:19 PM logoAcceleron: A Celgene Partner With A Promising Pipeline - Seeking Alpha (NASDAQ:XLRN) - September 13 at 5:46 AM logoAcceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : September 12, 2016 (NASDAQ:XLRN) - September 12 at 7:38 PM logoACCELERON PHARMA INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S (NASDAQ:XLRN) - September 12 at 7:38 PM
News IconShares Lower Over the Past Quarter: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) - September 11 at 5:37 AM
News IconNovo As buys $20,569,031 stake in Acceleron Pharma Inc (XLRN ... - National Daily Press (NASDAQ:XLRN) - September 9 at 7:48 PM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : September 9, 2016 (NASDAQ:XLRN) - September 9 at 7:48 PM logoETF’s with exposure to Acceleron Pharma, Inc. : September 8, 2016 (NASDAQ:XLRN) - September 8 at 12:07 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Expects To Hit Sales Of $251.47 - Investor Newswire (NASDAQ:XLRN) - September 6 at 8:18 PM
News IconShares Slipping Lower Over the Past Month: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) - September 1 at 11:34 AM logoAcceleron to Participate in Three Healthcare Investor Conferences in September (NASDAQ:XLRN) - September 1 at 11:34 AM
News IconHow is the Crowd Rating Acceleron Pharma Inc. (NASDAQ:XLRN) Shares? - Post News (NASDAQ:XLRN) - August 25 at 5:31 AM logoAnalysts See Sales Of $251.47 For Acceleron Pharma Inc. (NASDAQ:XLRN) - Investor Newswire (NASDAQ:XLRN) - August 22 at 5:46 AM
News IconStock Tracking Lower for the Quarter: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Post News (NASDAQ:XLRN) - August 20 at 7:48 PM logoAcceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy (NASDAQ:XLRN) - August 19 at 11:20 AM logoEarnings Surprise In Focus: Acceleron Pharma Inc. (NASDAQ:XLRN) - Investor Newswire (NASDAQ:XLRN) - August 16 at 8:27 PM logoACCELERON PHARMA INC Financials (NASDAQ:XLRN) - August 12 at 8:31 PM logoAcceleron Pharma Inc. (XLRN) Drops 7.89% on August 08 - (NASDAQ:XLRN) - August 10 at 11:39 AM logoAcceleron Pharma Inc. (XLRN) Drops 7.89% on August 08 (NASDAQ:XLRN) - August 9 at 8:42 PM logoAcceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:XLRN) - August 5 at 11:28 AM logoEdited Transcript of XLRN earnings conference call or presentation 4-Aug-16 12:00pm GMT (NASDAQ:XLRN) - August 4 at 8:51 PM logoAcceleron Pharma Inc.: Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results (NASDAQ:XLRN) - August 4 at 11:40 AM logoAcceleron reports 2Q loss (NASDAQ:XLRN) - August 4 at 11:40 AM logoAcceleron Pharma Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:XLRN) - August 4 at 11:40 AM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : July 29, 2016 (NASDAQ:XLRN) - July 29 at 8:29 AM logoAcceleron Pharma to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:XLRN) - July 28 at 7:00 AM


Acceleron Pharma (NASDAQ:XLRN) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff